TSXV:BTI.H - Post by User
Comment by
prophetoffactzon Dec 29, 2022 5:05pm
82 Views
Post# 35196063
RE:RE:RE:RE:Last day for tax-loss selling is today!
RE:RE:RE:RE:Last day for tax-loss selling is today! "But Bioasis, in the Chiesi deal, valued a single LSD at less than $750,000 up front and less than $35 million in milestone payments."
Chiesi's Fabry asset was still awaiting hard clinical data and was without FDA/European approvals or filings. Chiesi was not a strategic player in LSDs. It only hoped to be with Fabry as a strategic asset to build around. The xB3/Chiesi deal may have been for Fabry and three other small LSD opportunities. BTI kept the larger opportunities like Gauchers and Hunter for its pipeline, etc. BTI only licensed 4 LSDs to Chiesi.
What could the next Lysosomal Storage deal be like with Chiesi? Chiesi could have FDA and European approval for Fabry. Chiesi could have validated xB3 to an IND filing. With a strategic position in Lysosomal Storage xB3 becomes more strategic to Chiesi and more valuable should Chiesi wish to be a major player.
Biodexa could have clinical trial infrastructure to enter a development alliance for Hunter and Gauchers, etc., further adding value in a deal. The development alliance could cover all LSDs not in the current 4 LSD deal. If Chiesi likes xB3 it could even enter a broader licensing deal beyond LSDs. Perhaps Q-Sphera could also be part of an LSD and broader deal.
Biodexa says it will release preclinical Hunter data in Q2. What's that about since BTI has long ago released preclinical Hunter data from Scarpa. Being years behind Denali for Hunter ideally Biodexa has advanced the technology in some manner.